A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia
- 18 September 1990
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 66 (8), B22-B30
- https://doi.org/10.1016/0002-9149(90)90437-6
Abstract
A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia. The subjects were 290 patients taking lipid-lowering diets who were randomly assigned to 1 of the following treatment regimens for 14 weeks: lovastatin, 40 mg once a day with the morning meal (qam); lovastatin, 40 mg once a day with the evening meal (qpm); lovastatin 80 mg qpm; lovastatin, 40 mg twice daily, or probucol, 500 mg twice daily. One-third of the patients received probucol, and the other two-thirds were equally divided between the 4 lovastatin treatment groups. The mean reductions in total cholesterol in the 5 groups were, respectively, 20, 25, 30, 33 and 10%. The corresponding values for low-density lipoprotein cholesterol were 25, 32, 37, 40 and 8%. High-density lipoprotein cholesterol increased by 9 to 12% in all the lovastatin groups, but decreased by 23% in the probucol group. Triglycerides were reduced by 17 to 25% in all the lovastatin groups, but did not change significantly in the probucol group. Both drugs were well tolerated; no serious adverse events could be attributed to either agent. It is concluded that lovastatin is a considerably more effective lipid-lowering agent than probucol. In addition, lovastatin is almost as effective when given in a single daily dose as when given in a divided dose. When a once-a-day regimen is used, lovastatin is more effective if taken in the evening rather than the morning.Keywords
This publication has 18 references indexed in Scilit:
- Beyond CholesterolNew England Journal of Medicine, 1989
- Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.Circulation, 1989
- Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: The finnish multicenter studyThe American Journal of Cardiology, 1988
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988
- Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profilesAtherosclerosis, 1988
- A Multicenter Comparison of Lovastatin and Cholestyramine Therapy for Severe Primary HypercholesterolemiaPublished by American Medical Association (AMA) ,1988
- Probucol with Colestipol in the Treatment of HypercholesterolemiaAnnals of Internal Medicine, 1984
- Summary estimates of cholesterol used to predict coronary heart disease.Circulation, 1983
- Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemiaMetabolism, 1980
- Combining independent one-sample tests of significanceAnnals of the Institute of Statistical Mathematics, 1967